Search

everythinglearnresearchcommunity

for

Search:↓

A user's experience with Pyrilutamide, a topical treatment for hair loss that they used in combination with other treatments such as Minoxidil and Finasteride. The user experienced impressive results in a short amount of time.

A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.

A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

Factors that can cause hair loss other than DHT, such as inflammation and diet, and potential treatments like scalp massages, minoxidil, citrulline, stretches, meditation, iron sulfate/Vitamin C, Vitamin D, protein and Dutasteride.

User obsessed with hair loss prevention shares collection of treatments, including oral and topical finasteride, minoxidil, dermapen, and more. Others suggest adding RU58841, laser helmet, and PRP, while some advise dropping certain treatments for long-term manageability.

User shared 12-month hair growth progress using finasteride and dutasteride, with nizoral 3x per week. They experienced a finasteride shed but saw improvement after a year and offered advice for managing hair loss expectations.

Man experiences happiness after seeing himself with hair, discussing treatments like transplants, hair systems, Minoxidil, and Finasteride. Users share experiences, societal expectations, and desire for accessible solutions.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.

Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.